Patent · US Active

Dual mechanism inhibitors for the treatment of disease

US10174017B2 · kind B2 · utility

37Cited by

52References

31Claims

0Family size

Assignee

Aerie Pharmaceuticals, Inc. · US

Inventors

Mitchell A. deLong · Chapel Hill, US
Jill Marie Sturdivant · Chapel Hill, US
Susan M. Royalty · Cary, US

Key dates

Filing date	Mar 16, 2018
Grant date	Jan 8, 2019
Priority date	—
Expiry date	Mar 16, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07C2601/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.